

Appendix 1: Search strategy

	PubMed	EconLit	IBSS
	"Diabetes Mellitus"/economics[Mesh] OR "Insulin/economics"[Mesh] OR (diabetes[TI] OR insulin[TI] OR "oral antidiabetic"[TI] OR "oral antidiabetics"[TI] OR "sulfonylureas"[TI] OR "sulfonylurea"[TI] OR "oral antidiabetic drug"[TI] OR "oral antidiabetic drugs"[TI] OR "oral antidiabetic agent"[TI] OR "oral antidiabetic agents"[TI] OR "metformin"[TI] OR "diabetic"[TI] OR "Diabetes Mellitus"[Majr] OR "Insulin"[Majr])	ti(diabetes OR insulin OR "oral antidiabetic" OR "oral antidiabetics" OR "sulfonylureas" OR "sulfonylurea" OR "oral antidiabetic drug" OR "oral antidiabetic drugs" OR "oral antidiabetic agent" OR "oral antidiabetic agents" OR "metformin" OR "diabetic")	Diabetes OR insulin
AND	(cost OR costs OR "drug costs" OR costing OR "economic burden" OR expenditures OR "cost- effectiveness" OR "cost effectiveness" OR "economic evaluation" OR "economic analysis" OR "cost-benefit" or "cost benefit") OR ((cost[ti] OR costs[TI] OR "drug costs"[TI] OR costing[TI] OR "economic burden"[TI] OR expenditure[TI] OR expenditures[TI] OR "cost- effectiveness"[TI] OR "cost effectiveness"[TI] OR "economic evaluation"[TI] OR "economic analysis"[TI] OR "cost-benefit"[TI] OR "cost benefit"[TI] OR "payment"[TI] OR "medical spending")	(ti(cost OR costs OR "drug costs" OR costing OR "economic burden" OR expenditures OR "cost- effectiveness" OR "cost effectiveness" OR "economic evaluation" OR "economic analysis" OR "cost-benefit" OR "cost benefit" OR "medical spending") OR (cost OR costs OR "drug costs" OR costing OR "economic burden" OR expenditures OR "cost-effectiveness" OR "cost effectiveness" OR "economic evaluation" OR "economic analysis" OR "cost-benefit" OR "cost benefit" OR "medical spending"))	costs OR cost- effectiveness OR economic OR expenditure OR cost- benefit OR "economic burden"
AND	("africa"[Mesh] OR "Developing Countries"[Mesh] OR "South America"[Mesh] OR "Central America"[Mesh] OR "Latin America"[Mesh] OR "Mexico"[Mesh] OR "global" OR "developing countries" OR "poor countries" OR "resource-limited" OR "resource limited" OR "resource-poor" OR "resource poor" OR "low-income" OR "middle-income" OR "Albania" OR "Algeria" OR "American Samoa" OR "Angola" OR "Argentina" OR "Azerbaijan" OR "Belarus" OR "Belize" OR "Bosnia and Herzegovina" OR "Botswana" OR "Brazil" OR "Bulgaria" OR "China" OR "Colombia" OR "Costa Rica" OR "Cuba" OR "Dominica" OR "Dominican Republic" OR "Equatorial Guinea" OR "Ecuador" OR "Fiji" OR "Gabon" OR "Georgia" OR "Grenada" OR "Guyana" OR "Iran" OR "Iraq" OR "Jamaica" OR "Jordan" OR "Kazakhstan" OR "Lebanon" OR "Libya" OR "Macedonia" OR "Malaysia" OR "Maldives" OR "Marshall Islands" OR "Mauritius" OR "Mexico" OR	"africa" OR "Asia" OR "South America" OR "Central America" OR "Latin America" OR "global" OR "developing countries" OR "poor countries" OR "resource-limited" OR "resource limited" OR "resource-poor" OR "resource poor" OR "low- income" OR "middle-income" OR "Albania" OR "Algeria" OR "American Samoa" OR "Angola" OR "Argentina" OR "Azerbaijan" OR "Belarus" OR "Belize" OR "Bosnia and Herzegovina" OR "Botswana" OR "Brazil" OR "Bulgaria" OR "China" OR "Colombia" OR "Costa Rica" OR "Cuba" OR "Dominica" OR "Dominican Republic" OR "Equatorial Guinea" OR "Ecuador" OR "Fiji" OR "Gabon" OR "Georgia" OR "Grenada" OR "Guyana" OR "Iran" OR "Iraq" OR "Jamaica" OR "Jordan" OR "Kazakhstan" OR "Lebanon" OR "Libya" OR "Macedonia" OR "Malaysia" OR "Maldives" OR "Marshall Islands" OR "Mauritius" OR "Mexico" OR	"third world" AND "developing world"

	"Montenegro" OR "Namibia" OR "Palau" OR "Panama" OR "Paraguay" OR "Peru" OR "Romania" OR "Russian Federation" OR "Russia" OR "Serbia" OR "South Africa" OR "St. Lucia" OR "St. Vincent and the Grenadines" OR "St. Vincent" OR "Suriname" OR "Thailand" OR "Turkey" OR "Turkmenistan" OR "Tuvalu" OR "Venezuela" OR "Armenia" OR "Bangladesh" OR "Bhutan" OR "Bolivia" OR "Cabo Verde" OR "Cambodia" OR "Cameroon" OR "Congo" OR "Cote d'Ivoire" OR "Djibouti" OR "Egypt" OR "El Salvador" OR "Ghana" OR "Guatemala" OR "Honduras" OR "India" OR "Indonesia" OR "Kenya" OR "Kiribati" OR "Kosovo" OR "Kyrgyz Republic" OR "Lao PDR" OR "Lao" OR "Laos" OR "Lesotho" OR "Mauritania" OR "Micronesia" OR "Moldova" OR "Mongolia" OR "Morocco" OR "Myanmar" OR "Nicaragua" OR "Nigeria" OR "Pakistan" OR "Papua New Guinea" OR "Philippines" OR "Samoa" OR "Sao Tome and Principe" OR "Solomon Islands" OR "Sri Lanka" OR "Sudan" OR "Swaziland" OR "Syrian Arab Republic" OR "Syria" OR "Tajikistan" OR "Timor-Leste" OR "Tonga" OR "Tunisia" OR "Ukraine" OR "Uzbekistan" OR "Vanuatu" OR "Vietnam" OR "West Bank" OR "Gaza" OR "Yemen" OR "Zambia" OR "Afghanistan" OR "Benin" OR "Burkina Faso" OR "Burundi" OR "Central African Republic" OR "Chad" OR "Comoros" OR "Eritrea" OR "Ethiopia" OR "Gambia" OR "Guinea" OR "Guinea-Bissau" OR "Haiti" OR "Korea" OR "Liberia" OR "Madagascar" OR "Malawi" OR "Mali" OR "Mozambique" OR "Nepal" OR "Niger" OR "Rwanda" OR "Senegal" OR "Sierra Leone" OR "Somalia" OR "South Sudan" OR "Tanzania" OR "Togo" OR "Uganda" OR "Zimbabwe")	"Montenegro" OR "Namibia" OR "Palau" OR "Panama" OR "Paraguay" OR "Peru" OR "Romania" OR "Russian Federation" OR "Russia" OR "Serbia" OR "South Africa" OR "St. Lucia" OR "St. Vincent and the Grenadines" OR "St. Vincent" OR "Suriname" OR "Thailand" OR "Turkey" OR "Turkmenistan" OR "Tuvalu" OR "Venezuela" OR "Armenia" OR "Bangladesh" OR "Bhutan" OR "Bolivia" OR "Cabo Verde" OR "Cambodia" OR "Cameroon" OR "Congo" OR "cote d'Ivoire" OR "Djibouti" OR "Egypt" OR "El Salvador" OR "Ghana" OR "Guatemala" OR "Honduras" OR "India" OR "Indonesia" OR "Kenya" OR "Kiribati" OR "Kosovo" OR "Kyrgyz Republic" OR "Lao PDR" OR "Lao" OR "Laos" OR "Lesotho" OR "Mauritania" OR "Micronesia" OR "Moldova" OR "Mongolia" OR "Morocco" OR "Myanmar" OR "Nicaragua" OR "Nigeria" OR "Pakistan" OR "Papua New Guinea" OR "Philippines" OR "Samoa" OR "Sao tome and Principe" OR "Solomon Islands" OR "Sri Lanka" OR "Sudan" OR "Swaziland" OR "Syrian Arab Republic" OR "Syria" OR "Tajikistan" OR "Timor-Leste" OR "Tonga" OR "Tunisia" OR "Ukraine" OR "Uzbekistan" OR "Vanuatu" OR "Vietnam" OR "West Bank" OR "Gaza" OR "Yemen" OR "Zambia" OR "Afghanistan" OR "Benin" OR "Burkina Faso" OR "Burundi" OR "Central African Republic" OR "Chad" OR "Comoros" OR "Eritrea" OR "Ethiopia" OR "Gambia" OR "Guinea" OR "Guinea-Bissau" OR "Haiti" OR "Korea" OR "Liberia" OR "Madagascar" OR "Malawi" OR "Mali" OR "Mozambique" OR "Nepal" OR "Niger" OR "Rwanda" OR "Senegal" OR "Sierra Leone" OR "Somalia" OR "South Sudan" OR "Tanzania" OR "Togo" OR "Uganda" OR "Zimbabwe"	
AND	"2007"[Date - Publication] : "3000"[Date - Publication]		
Other constraints:		Peer reviewed: Yes Published after: 1 January 2007	

Appendix 2: Inflation rate Adjustment

Year	Conversion (CPI)
2007	240.007/207.3
2008	240.007/215.303
2009	240.007/214.537
2010	240.007/218.056
2011	240.007/224.939
2012	240.007/229.594
2013	240.007/232.957
2014	240.007/236.736
2015	240.007/237.017
2016	No conversion

Appendix 3: Descriptive information about included studies

Authors and year	Country	Reference	Where found in text	Diabetes type	Site, source	Funding source
Shrestha, Lohani et al. 2013	Nepal	¹	Table 1	Unspecified	Public hospital (n=1), private hospital (n=1), outpatient polyclinics (n=2); patient interviews (n=227)	None reported
Bermudez-Tamayo, Besançon et al. 2017	Mali	²	Table 1	Unspecified	National diabetes registry; patient interviews (n=497)	International Diabetes Federation (funds from Merck and Co., Novo Nordisk, Eli Lilly and Co., Takeda Pharmaceuticals, GSK Inc.)
Skordis-Worrall, Round et al. 2017	Kyrgyzstan	³	Table 1	1 and 2	Unspecified (n=unspecified); patient interviews (n=138)	University College London
Tharkar, Devarajan et al. 2010	India	⁴	Table 1	Unspecified	Population-based survey; patient interviews (n=718)	None reported
Kumpatla, Kothandan et al. 2013	India	⁵	Table 1	2	Diabetes care center (n=1); patient interviews (n=487)	None reported
Chandra, Gogate et al. 2014	India	⁶	Table 1	Unspecified	Diabetes clinic (n=2) and ophthalmology clinic (n=1); patient interviews (n=219)	Community Eye Care Foundation
Katam, Bhatia et al. 2016	India	⁷	Table 1	1	Diabetes clinic at public teaching hospital (n=1); patient interviews (n=88)	None reported
Tin, Iro et al. 2015	Solomon Islands	⁸	Tables 1, 4	2	Diabetes clinic (n=1); patient interviews (n=197)	World Diabetes Foundation, Solomon Islands MHMS, Nauru MHMS, International Centre for Eyecare Education at the University of New South Wales, Australia and New Zealand Society of Nephrologists
Javanbakht, Baradaran et al. 2011	Iran	⁹	Table 1	2	Diabetes clinics; patient interviews (n=unspecified)	None reported
Wang, McGreevey et al. 2009	China	¹⁰	Table 1, Appendix A4-1	2	Population-based survey; patient interviews (n=2040)	GlaxoSmithKline
Yang, Zhao et al. 2012	China	¹¹	Table 1	Unspecified	Population-based survey; patient interviews (n=1481)	International Diabetes Federation (IDF), Chinese Diabetes Society

Le, Lin et al. 2013	China	¹²	Table 1	2	Population-based survey; patient interviews (n=9396)	National Natural Science Fund of China, Yunnan Provincial Natural Science Fund
Chereches, Litan et al. 2012	Romania	¹³	Table 1	Unspecified	Diabetes care center; patient interviews (n=1150)	National Institutes of Health
Afroz, Chowdhury et al. 2016	Bangladesh	¹⁴	Table 2, Appendix A4-2	2	Secondary/tertiary hospital (n=1); record review	Bangladesh Diabetic Somiti
Aghili, Khamseh et al. 2012	Iran	¹⁵	Table 2	2	Diabetes outpatient setting (n=1); price lists	DarmanYab Darou Co.; Roche Diagnostics GmbH
Riewpaiboon, Chatterjee et al. 2011	Thailand	¹⁶	Table 2	1 and 2	District hospital (n=1); record review	Asian Scholarship Foundation, Ford Foundation
He, Ma et al. 2015	China	¹⁷	Table 2	1 and 2	Teaching hospital (n=1); record review	None reported
Bao, Yang et al. 2016	China	¹⁸	Table 2	2	Hospitals (n=38); record review	None reported
Garcia, Villarreal et al. 2015	Mexico	¹⁹	Table 2	2 with polypharmacy	Primary health care facilities (n=2); record review	None reported
Diaz de Leon-Castaneda, Altagracia-Martinez et al. 2012	Mexico	²⁰	Tables 3, 4	2	Primary care clinic (n=1); price lists	None reported
Codogno, Fernandes et al. 2011	Brazil	²¹	Table 2	2	Primary outpatient facility (n=1); record review	None reported
Cobas, Ferraz et al. 2013	Brazil	²²	Tables 2, 4, Appendix A4-2	1	Secondary and tertiary public health clinics (n=28); price lists	Farmanguinhos/Fundação Oswaldo Cruz/National Health Ministry, Brazilian Diabetes Society, Fundação do Amparo à Pesquisa do Estado do Rio de Janeiro and the Conselho Nacional de Desenvolvimento Científico e Tecnológico do Brasil
Celik, Asci et al. 2015	Turkey	²³	Table 2	2	Secondary/tertiary hospital (n=1); record review	None reported
Gonzalez, Elgart et al. 2013	Argentina	²⁴	Table 2	1 and 2	HMO (n=1); record review	Health Carrillo-Oñativia
Akari, Mateti et al. 2013	India	²⁵	Table 3 Appendix A4-2	Unspecified	Specialty hospital (n=1); patient interviews + record review	None reported
Fadare, Olamoyegun et al. 2015	Nigeria	²⁶	Table 3	1 and 2	Teaching hospital (n=1); patient interviews + price lists	None reported

Chatterjee, Riewpaiboon et al. 2011	Thailand	²⁷	Table 3, Appendix A4-1	1 and 2	District hospital (n=1); patient interviews + record review	Asian Scholarship Foundation
Wang, Fu et al. 2009	China	²⁸	Table 3	2	Hospitals (n=20); patient interviews + record review	GlaxoSmithKline
Bahia, Araujo et al. 2011	Brazil	²⁹	Table 3, Appendix A4-2	2	Primary, secondary and tertiary facilities (n unclear); patient interviews + price lists	Brazilian Diabetes Society, Sanofi Aventis, Eli Lilly
Borges, Ferraz et al. 2014	Brazil	³⁰	Table 3	2	Tertiary diabetes care center (n=1); patient interviews + price lists	None reported
Elgart, Asteazaran et al. 2014	Argentina	³¹	Table 3	2	Private hospital (n=1); patient interviews + record review	Novo Nordisk International
Ogle, Kim et al. 2016	Benin, Burkina Faso, Cambodia, Central African Republic, Cote d'Ivoire, Ecuador, India, Malawi, Mauritania, Mongolia, Nepal, Pakistan, Somalia, St. Lucia	³²	Table 4	1	Survey of medical centers (n=20)	University of Sydney, NHMRC Clinical Trials Centre, Leona M. and Harry B. Helmsley Charitable Trust
Flessa and Zembok 2014	Cambodia	³³	Table 4	2	National price list	German Federal Ministry for Economic Cooperation and Development (BMZ) via Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH
Sosale, Sosale et al. 2016	India	³⁴	Table 4	2	Private hospital (n=1); record review	Diacon Hospital
Davari, Boroumand et al. 2016	Iran	³⁵	Table 4	2	Endocrine research center (n=1); record review	Isfahan University of Medical Sciences
Farshchi, Aghili et al. 2016	Iran	³⁶	Table 4	2 with complications	Public diabetes care center (n=1); record review	Novo Nordisk
Al-Sharayri, Alsabrah et al. 2013	Jordan	³⁷	Table 4	Unspecified	Outpatient pharmacy at a hospital (n=1); record review	None reported
Hyassat, Al Shekarchi et al. 2015	Jordan	³⁸	Table 4	2	Cohort study at national diabetes center; record review	None reported

Biorac, Jakovljević et al. 2009	Serbia	³⁹	Table 4	2	Health center (n=2); patient interviews + price lists	None reported
Petkova, Petkova et al. 2013	Bulgaria	⁴⁰	Table 4	1 (pediatric)	Pediatric hospital (n=1); patient interviews	None reported
Huang, Vemer et al. 2016	China	⁴¹	Table 4	Unspecified	Population-based cohort study; record review	None reported
Borges, Guidoni et al. 2011	Brazil	⁴²	Table 4	2	Diabetes outpatient facility (n=1); record review	Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Tecnológico e Científico
Beran and Higuchi 2013	Vietnam, Philippines	⁴³	Table 4	Unspecified	Diabetes “centers of excellence” and facilities (n unclear); patient interviews + record review	World Diabetes Foundation, International Diabetes Federation (funds from Lilly Foundation), Foundation for Advanced Studies on International Development, Health Action International
Gu, Mu et al. 2016	China	⁴⁴	Table 4	2	Secondary and tertiary hospitals (n=2); record review	AstraZeneca
Gu, Deng et al. 2015	China	⁴⁵	Table 4	2	Secondary and tertiary hospitals (n=2); record review	AstraZeneca
Elgart, González et al. 2014	Argentina	⁴⁶	Table 4	2	Pharmaceutical management system; record review	Novo Nordisk
Okoronkwo, Ekpemiro et al. 2016	Nigeria	⁴⁷	Appendix A4-1	2	Outpatient diabetes clinic at public health facility (n=1); patient interviews	None reported
Farshchi, Esteghamati et al. 2014	Iran	⁴⁸	Appendix A4-1	2	Public diabetes care center (n=1); record review	None reported
Cárdenas, Mirelman et al. 2015	Peru	⁴⁹	Appendix A4-1	2	National price list	National Institutes of Health
Chicaíza-Becerra, Gamboa-Garay et al. 2010	Colombia	⁵⁰	Appendix A4-1	2	National price list	Universidad Nacional de Colombia
Riewpaiboon, Chatterjee et al. 2011	Thailand	⁵¹	Appendix A4-1	1 and 2	Public district hospital (n=1); patient interviews + record review	Ford Foundation
Oksuz, Malhan et al. 2016	Turkey	⁵²	Appendix A4-2	Unspecified (with complication)	National price list	None reported

Appendix 4: Complication treatment costs

Table A4-1: Complication treatment costs, per case per year

Study type	Country/study	Cost component (2016 USD)	
		Type of complication/procedure	Cost per case per year
Data reported by patients	<i>Lower-middle income countries</i>		
	Nigeria ⁴⁷	Diabetes related diseases conditions (unspecified)	218.72
	<i>Upper-middle income countries</i>		
	China ¹⁰	Hypertension	1,963.7
		Stroke	1,324.26
		Acute MI	1,577.12
		Transient Ischemia Attack	1,324.61
		Angina	1,156.73
		Congestive heart failure	1,080.90
		PTCA	4,033.00
		Renal function disorders	984.80
		Macroalbuminuria	1,175.72
		Microalbuminuria	835.57
		Uremia	249.73
		Cataract	1,504.41
		Retinopathy	907.70
Peripheral neuropathy		1,228.05	
Other CHD	2,737.56		
Peripheral vascular disease	117.40		
Data from provider/system perspective	<i>Upper-middle income countries</i>		
	Iran ⁴⁸	Neuropathy & foot ulcer	80.59
		Nephropathy	150.35
		Retinopathy	81.73
		CVD	221.67
	Peru ⁴⁹	Diabetic Foot	193.39
	Colombia ⁵⁰	Major amputation	2,155.11
		Minor amputation	866.25
		Bone biopsy	137.71
		Cellulitis	199.82
		Ischemia management	1,419.89

		Osteomyelitis	
		Rehabilitation	45.61
		Magnetic resonance	315.35
		Radiography	15.49
		Deep ulcer management	1,630.32
		Superficial ulcer management	581.08
Data from both patient and provider perspectives	<i>Upper-middle income countries</i>		
	Thailand ²⁷	Micro vascular	714.77
		Macro vascular	408.61
		Micro and macro vascular complications	742.89
		Micro vascular and cataract	830.97
		Cataract	168.39
	Thailand ⁵¹	Diabetes with complications	4,368.42
		Diabetes with disability	7925.64
		Diabetes with mild disability	5301.49
		Diabetes with moderate disability	16,284.76
		Diabetes with severe disability	14,356.52
		Diabetes with very severe disability	21,703.00

Table A4-2: Complication treatment costs, per patient per year

	Country/study	Cost component (2016 USD)	
		Type of complication	Cost per patient per year
Data from provider/system perspective	<i>Lower-middle income countries</i>		
	Bangladesh ¹⁴	Cardiopathy–retinopathy	596.00
		Cardiopathy–nephropathy	478.00
		Nephropathy–retinopathy	867.00
		Cardiopathy–retinopathy	596.00
		Cardiopathy–nephropathy	478.00
	<i>Upper-middle income countries</i>		
Brazil ²²	Medical procedures/ hemodialysis	84.62	
Data from both patient and provider perspectives	<i>Lower-middle income countries</i>		
	India ²⁵	Macro vascular	134.85
		Micro vascular	88.48
		Infections	51.29

	<i>Upper-middle income countries</i>		
	Brazil ²⁹	Micro vascular	3,703.73
		Macro vascular	2,387.33
		Micro and macro vascular complications	2,976.64
	Turkey ⁵²	Diabetic foot ulcer	213.21

References

1. Shrestha N, Lohani SP, Angdembe MR, et al. Cost of diabetes mellitus care among patients attending selected outpatient clinics. *Journal of the Nepal Medical Association* 2013;52(190):343-8. [published Online First: 2013/12/24]
2. Bermudez-Tamayo C, Besançon S, Johri M, et al. Direct and indirect costs of diabetes mellitus in Mali: A case-control study. *PLoS One* 2017;12(5):e0176128.
3. Skordis-Worrall J, Round J, Arnold M, et al. Addressing the double-burden of diabetes and tuberculosis: lessons from Kyrgyzstan. *Globalization and Health* 2017;13(1):16.
4. Tharkar S, Devarajan A, Kumpatla S, et al. The socioeconomics of diabetes from a developing country: A population based cost of illness study. *Diabetes Research and Clinical Practice* 2010;89(3):334-40. doi: 10.1016/j.diabres.2010.05.009 [published Online First: 2010/06/12]
5. Kumpatla S, Kothandan H, Tharkar S, et al. The costs of treating long term diabetic complications in a developing country: A study from India. *Journal of the Association of Physicians of India* 2013;61:17.
6. Chandra P, Gogate B, Gogate P, et al. Economic burden of diabetes in urban Indians. *Open Ophthalmology Journal* 2014;8:91-4. doi: 10.2174/1874364101408010091 [published Online First: 2015/02/13]
7. Katam KK, Bhatia V, Dabadghao P, et al. High direct costs of medical care in patients with Type 1 diabetes attending a referral clinic in a government-funded hospital in Northern India. *National Medical Journal of India* 2016;29(2):64-7. [published Online First: 2016/09/03]
8. Tin ST, Iro G, Gadabu E, et al. Counting the cost of diabetes in the Solomon Islands and Nauru. *PLoS One* 2015;10(12):e0145603. doi: 10.1371/journal.pone.0145603 [published Online First: 2015/12/25]
9. Javanbakht M, Baradaran HR, Mashayekhi A, et al. Cost-of-illness analysis of type 2 diabetes mellitus in Iran. *PLoS One* 2011;6(10):e26864. doi: 10.1371/journal.pone.0026864 [published Online First: 2011/11/09]
10. Wang W, McGreevey WP, Fu C, et al. Type 2 diabetes mellitus in China: A preventable economic burden. *American Journal of Managed Care* 2009;15(9):593-601. [published Online First: 2009/09/15]
11. Yang W, Zhao W, Xiao J, et al. Medical care and payment for diabetes in China: Enormous threat and great opportunity. *PLoS One* 2012;7(9):e39513. doi: 10.1371/journal.pone.0039513 [published Online First: 2012/10/11]
12. Le C, Lin L, Jun D, et al. The economic burden of type 2 diabetes mellitus in rural southwest China. *International journal of cardiology* 2013;165(2):273-7. doi: 10.1016/j.ijcard.2011.08.039 [published Online First: 2011/09/13]
13. Chereches RM, Litan CM, Zlati AM, et al. Does co-morbid depression impact diabetes related costs? Evidence from a cross-sectional survey in a low-income country. *Journal of Mental Health Policy and Economics* 2012;15(3):127-38. [published Online First: 2012/09/25]
14. Afroz A, Chowdhury HA, Shahjahan M, et al. Association of good glycemic control and cost of diabetes care: Experience from a tertiary care hospital in Bangladesh. *Diabetes Research and Clinical Practice* 2016;120:142-8. doi: 10.1016/j.diabres.2016.07.030 [published Online First: 2016/08/24]
15. Aghili R, Khamseh ME, Malek M, et al. Structured self monitoring of blood glucose in Iranian people with type 2 diabetes; A cost consequence analysis. *DARU Journal of Pharmaceutical Sciences* 2012;20(1):32.
16. Riewpaiboon A, Chatterjee S, Piyathakit P. Cost analysis for efficient management: diabetes treatment at a public district hospital in Thailand. *International Journal of Pharmacy Practice* 2011;19(5):342-9. doi: 10.1111/j.2042-7174.2011.00131.x [published Online First: 2011/09/09]
17. He M, Ma J, Wang D, et al. Costs for hospitalized patients with diabetes mellitus in China. *Asia Pacific Journal of Public Health* 2015;27(2):NP925-NP35.

18. Bao X, Yang C, Fang K, et al. Hospitalization costs and complications in hospitalized patients with type 2 diabetes mellitus in Beijing, China. *Journal of diabetes* 2016 doi: 10.1111/1753-0407.12428 [published Online First: 2016/05/20]
19. Garcia AL, Villarreal RE, Galicia RL, et al. [The cost of polypharmacy in patients with type 2 diabetes mellitus]. *Revista Médica de Chile* 2015;143(5):606-11. doi: 10.4067/s0034-98872015000500008 [published Online First: 2015/07/24]
20. de León-Castañeda CD, Altagracia-Martínez M, Kravzov-Jinich J, et al. Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City. *ClinicoEconomics and Outcomes Research* 2012;4:57.
21. Codogno JS, Fernandes RA, Sarti FM, et al. The burden of physical activity on type 2 diabetes public healthcare expenditures among adults: A retrospective study. *BMC Public Health* 2011;11:275. doi: 10.1186/1471-2458-11-275 [published Online First: 2011/05/06]
22. Cobas RA, Ferraz MB, Matheus ASdM, et al. The cost of type 1 diabetes: A nationwide multicentre study in Brazil. *Bulletin of the World Health Organization* 2013;91(6):434-40.
23. Celik A, Asci M, Celik BO, et al. The impact of laparoscopic diverted sleeve gastrectomy with ileal transposition (DSIT) on short term diabetic medication costs. *SpringerPlus* 2015;4:417. doi: 10.1186/s40064-015-1216-z [published Online First: 2015/08/22]
24. Gonzalez L, Elgart JF, Calvo H, et al. Changes in quality of care and costs induced by implementation of a diabetes program in a social security entity of Argentina. *ClinicoEconomics and Outcomes Research* 2013;5:337-45. doi: 10.2147/ceor.s40949 [published Online First: 2013/07/23]
25. Akari S, Mateti UV, Kunduru BR. Health-care cost of diabetes in South India: A cost of illness study. *Journal of research in pharmacy practice* 2013;2(3):114-7. doi: 10.4103/2279-042x.122382 [published Online First: 2014/07/06]
26. Fadare J, Olamoyegun M, Gbadegesin BA. Medication adherence and direct treatment cost among diabetes patients attending a tertiary healthcare facility in Ogbomosho, Nigeria. *Malawi Medical Journal: The Journal of Medical Association of Malawi* 2015;27(2):65-70. [published Online First: 2015/09/26]
27. Chatterjee S, Riewpaiboon A, Piyauthakit P, et al. Cost of diabetes and its complications in Thailand: A complete picture of economic burden. *Health & social care in the community* 2011;19(3):289-98. doi: 10.1111/j.1365-2524.2010.00981.x [published Online First: 2011/02/01]
28. Wang W, Fu CW, Pan CY, et al. How do type 2 diabetes mellitus-related chronic complications impact direct medical cost in four major cities of urban China? *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research* 2009;12(6):923-9. doi: 10.1111/j.1524-4733.2009.00561.x [published Online First: 2009/10/14]
29. Bahia LR, Araujo DV, Schaan BD, et al. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research* 2011;14(5 Suppl 1):S137-40. doi: 10.1016/j.jval.2011.05.009 [published Online First: 2011/08/24]
30. Borges NB, Ferraz MB, Chacra AR. The cost of type 2 diabetes in Brazil: evaluation of a diabetes care center in the city of Sao Paulo, Brazil. *Diabetology & metabolic syndrome* 2014;6(1):122. doi: 10.1186/1758-5996-6-122 [published Online First: 2014/11/18]
31. Elgart JF, Asteazaran S, De La Fuente JL, et al. Direct and indirect costs associated to type 2 diabetes and its complications measured in a social security institution of Argentina. *International journal of public health* 2014;59(5):851-7. doi: 10.1007/s00038-014-0604-4 [published Online First: 2014/09/06]
32. Ogle G, Kim H, Middlehurst A, et al. Financial costs for families of children with Type 1 diabetes in lower-income countries. *Diabetic Medicine* 2016;33(6):820-26.
33. Flessa S, Zembok A. Costing of diabetes mellitus type II in Cambodia. *Health Economics Review* 2014;4(1):24.

34. Sosale B, Sosale A, Bhattacharyya A. Clinical effectiveness and impact on insulin therapy cost after addition of dapagliflozin to patients with uncontrolled type 2 diabetes. *Diabetes Therapy* 2016;7(4):765-76.
35. Davari M, Boroumand Z, Amini M, et al. The direct medical costs of outpatient cares of Type 2 diabetes in Iran: A retrospective study. *International Journal of Preventive Medicine* 2016;7
36. Farshchi A, Aghili R, Oskuee M, et al. Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study. *BMC Endocrine Disorders* 2016;16(1):35.
37. Al-Sharayri MG, Alsabrah TM, Aljbori TM. Insulin vials vs. insulin cartridges: Further cost considerations. *Saudi Pharmaceutical Journal* 2013;21(2):225-27.
38. Hyassat D, Al Shekarchi N, Jaddou H, et al. Are insulin analogues an unavoidable necessity for the treatment of type 2 diabetes in developing countries? The case of Jordan. *Eastern Mediterranean Health Journal* 2015;21(10):729.
39. Biorac N, Jakovljević MB, Stefanović D, et al. Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia. *Vojnosanitetski Pregled* 2009;66(4):271-76.
40. Petkova E, Petkova V, Konstantinova M, et al. Economic evaluation of continuous subcutaneous insulin infusion for children with diabetes—a pilot study: CSII application for children—economic evaluation. *BMC Pediatrics* 2013;13(1):155.
41. Huang Y, Vemer P, Zhu J, et al. Economic burden in Chinese patients with diabetes mellitus using electronic insurance claims data. *PloS One* 2016;11(8):e0159297.
42. Borges APdS, Guidoni CM, Freitas Od, et al. Economic evaluation of outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service. *Arquivos Brasileiros de Endocrinologia & Metabologia* 2011;55(9):686-91.
43. Beran D, Higuchi M. Delivering diabetes care in the Philippines and Vietnam: Policy and practice issues. *Asia Pacific Journal of Public Health* 2013;25(1):92-101.
44. Gu S, Mu Y, Zhai S, et al. Cost-effectiveness of dapagliflozin versus acarbose as a monotherapy in type 2 diabetes in China. *PloS One* 2016;11(11):e0165629.
45. Gu S, Deng J, Shi L, et al. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China. *Journal of Medical Economics* 2015;18(10):808-20.
46. Elgart JF, González L, Rucci E, et al. Self-monitoring of blood glucose: use, frequency drivers, and cost in Argentina. *Journal of Diabetes Science and Technology* 2014;8(6):1121-25.
47. Okoronkwo I, Ekpemiro J, Onwujekwe O, et al. Socioeconomic inequities and payment coping mechanisms used in the treatment of type 2 diabetes mellitus in Nigeria. *Nigerian Journal of Clinical Practice* 2016;19(1):104-09.
48. Farshchi A, Esteghamati A, Sari AA, et al. The cost of diabetes chronic complications among Iranian people with type 2 diabetes mellitus. *Journal of Diabetes & Metabolic Disorders* 2014;13(1):42.
49. Cárdenas MK, Mirelman AJ, Galvin CJ, et al. The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru. *BMC Health Services Research* 2015;15(1):483.
50. Chicaíza-Becerra LA, Gamboa-Garay O, García-Molina M. Costo-efectividad del uso de resonancia magnética y radiografía convencional en pacientes con pie diabético. *Revista de Salud Pública* 2010;12(6):974-81.
51. Riewpaiboon A, Chatterjee S, Riewpaiboon W, et al. Disability and cost for diabetic patients at a public district hospital in Thailand. *International Journal of Pharmacy Practice* 2011;19(2):84-93.
52. Oksuz E, Malhan S, Sonmez B, et al. Cost of illness among patients with diabetic foot ulcer in Turkey. *World Journal of Diabetes* 2016;7(18):462.